Vineet Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held today i.e., on Thursday, November 27, 2025, approved the following:1. Raise of funds by way of issue of equity shares of the Company of face value Rs.10/- (RupeeTen Only) each for an aggregate amount not exceeding Rs.3,000 Lakhs (Rupees ThreeThousand Lakhs) on Right issue basis, on such terms and conditions as may be decided bythe Board of Directors / Rights Issue Committee to the eligible equity shareholders of theCompany, as on the record date (to be notified subsequently).The issue is subject to the receipt of applicable regulatory, statutory approvals, inaccordance with the provisions of the Securities and Exchange Board of India (Issue ofCapital and Disclosure Requirements) Regulations, 2018, Securities and Exchange Board ofIndia (Listing Obligations and Disclosure Requirements), Regulations, 2015, and theCompanies Act, 2013 and the rules made thereunder, as amended from time to time.2. Constitution of the Rights Issue Committee, consisting of Mr. Gaddam Venkata Ramana,Mr. Satyanarayana Raju Bhupathiraju, Mr. Premananda Reddy Vennapusa, Mr. Dilip VishnuAcharekar empowering them to undertake all the necessary activities for the completion ofthe proposed Rights Issue.
VINEETLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vineet Laboratories Limited's Board of Directors, at its meeting on November 27, 2025, approved raising funds up to Rs. 3,000 Lakhs (Rs. 30 Crores) through a Rights Issue of equity shares with a face value of Rs. 10 each. The issue will be offered to eligible equity shareholders as on a record date, which will be notified later. The fundraise is subject to regulatory and statutory approvals under SEBI ICDR Regulations, SEBI LODR Regulations, and the Companies Act, 2013. The Board also constituted a Rights Issue Committee comprising four directors to oversee the completion of the issue.
Eligible shareholders will get the opportunity to subscribe to additional shares in proportion to their existing holdings, which may dilute non-participating shareholders. The fresh capital infusion could strengthen the company's balance sheet, though the specific end-use of funds has not been disclosed.